Colorectal Cancer Clinical Trials in New York, New York

44 studies are recruiting for colorectal cancer in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Researching the Effect of Exercise on Cancer

    Researchers think that exercise may be able to prevent cancer from coming back by lowering ctDNA levels. The purpose of this study is to explore how aerobic exercise (exercise that stimulates and strengthens the heart and lungs and improves the body's use of oxygen) can reduce the level of ctDNA fo…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    9 in total
    Run by
    City of Hope Medical Center

    See if you can join NCT04589468 on ClinicalTrials.gov

  2. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

    This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansio…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mt. Sinai, New York, New York
    Locations
    54 in total
    Run by
    Genmab

    See if you can join NCT03526835 on ClinicalTrials.gov

  3. FITting Non-invasive Tests in Lynch Syndrome Surveillance

    The purpose of this clinical study is to evaluate the accuracy of the fecal immunochemical test (FIT) in comparison to colonoscopy in patients with Lynch Syndrome (LS) who are undergoing colonoscopy surveillance.

    Stage
    Not phased
    Ages
    20 to 80
    Site
    Columbia University, New York, New York
    Locations
    3 in total
    Run by
    University of Chicago

    See if you can join NCT06898996 on ClinicalTrials.gov

  4. A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

    Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surg…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0324), New York, New York
    Locations
    55 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06428409 on ClinicalTrials.gov

  5. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

    Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    22 in total
    Run by
    Astellas Pharma Inc

    See if you can join NCT07094204 on ClinicalTrials.gov

  6. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a sui…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan-Kettering Cancer Center, New York, New York
    Locations
    104 in total
    Run by
    Boehringer Ingelheim

    See if you can join NCT06324357 on ClinicalTrials.gov

  7. Lead-212 PSV359 Therapy for Patients With Solid Tumors

    Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

    Stage
    Phase 1
    Ages
    18 to 90
    Site
    Memorial Sloan Kettering Cancer Center - Main Campus, New York, New York
    Locations
    16 in total
    Run by
    Perspective Therapeutics

    See if you can join NCT06710756 on ClinicalTrials.gov

  8. [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

    This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of [18F]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast can…

    Stage
    Phase 1
    Ages
    18 to 80
    Site
    Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York, New York
    Locations
    2 in total
    Run by
    Blue Earth Diagnostics

    See if you can join NCT07432633 on ClinicalTrials.gov

  9. Malignant Polyp Registry

    The purpose of this study is to learn more about malignant colorectal polyps (early colorectal cancers removed during colonoscopy) and the risk that cancer remains, comes back, or spreads after the polyp is removed. The researchers also want to understand how patients and doctors make decisions abo…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07619079 on ClinicalTrials.gov

  10. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

    Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

    Stage
    Not phased
    Ages
    18 and older
    Site
    NYU Langone Medical Center, New York, New York
    Locations
    16 in total
    Run by
    A2 Biotherapeutics Inc.

    See if you can join NCT04981119 on ClinicalTrials.gov

  11. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

    This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Perlmutter Cancer Center at NYU Langone Health (contact for more locations), New York, New York
    Locations
    30 in total
    Run by
    Verastem, Inc.

    See if you can join NCT07659795 on ClinicalTrials.gov

  12. Collection of Information to Better Understand Young Onset Colorectal Cancer

    The purpose of this registry study is to create a database-a collection of information-for better understanding young onset colorectal cancer. Colorectal cancer patients are considered to have young onset colorectal cancer if they are diagnosed with their cancer before the age of 50. Researchers wi…

    Stage
    Not phased
    Ages
    18 and older
    Site
    MSK at Ralph Lauren, New York, New York
    Locations
    8 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04489238 on ClinicalTrials.gov

  13. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Laura & Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
    Locations
    20 in total
    Run by
    Verastem, Inc.

    See if you can join NCT07020221 on ClinicalTrials.gov

  14. A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

    A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer

    Stage
    Phase 2
    Ages
    18 and older
    Site
    NYU Langone Health, New York, New York
    Locations
    13 in total
    Run by
    Criterium, Inc.

    See if you can join NCT06992258 on ClinicalTrials.gov

  15. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York, New York
    Locations
    49 in total
    Run by
    Institut de Recherches Internationales Servier

    See if you can join NCT05786924 on ClinicalTrials.gov

  16. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    33 in total
    Run by
    Parabilis Medicines, Inc.

    See if you can join NCT05919264 on ClinicalTrials.gov

  17. Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

    The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering, New York, New York
    Locations
    21 in total
    Run by
    Bicara Therapeutics

    See if you can join NCT04429542 on ClinicalTrials.gov

  18. Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

    Genetic testing is a type of test that detects changes to the genes-the DNA instructions that are passed on from the mother and father. The results of a genetic test can confirm whether the participant has a genetic disorder, which is a disease caused in whole or in part by changes to the genes. Ge…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities), New York, New York
    Locations
    4 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04751435 on ClinicalTrials.gov

  19. A Study of Mental Health Care in People With Cancer

    The purpose of this study is to look at mental health services for adults with depressed mood who were diagnosed with cancer at the age of 65 or older. This study will compare the usual approach for connecting older adults with depressed mood to mental health services with the Open Door for Cancer …

    Stage
    Not phased
    Ages
    65 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06037954 on ClinicalTrials.gov

  20. AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

    This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumors that are likely to be FAP positive. The study consists of an initial Phase 1…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    7 in total
    Run by
    Avacta Life Sciences Ltd

    See if you can join NCT07454642 on ClinicalTrials.gov

  21. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage
    Phase 1
    Ages
    12 and older
    Site
    Memorial Sloan Kettering, New York, New York
    Locations
    76 in total
    Run by
    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

  22. Colonoscopy vs Stool Testing for Older Adults With Colon Polyps

    This is a multi-site comparative effectiveness randomized controlled trial (RCT) comparing annual fecal immunochemical testing (FIT) and colonoscopy for post-polypectomy surveillance among adults aged 65-82 with a history of colorectal polyps who are due for surveillance colonoscopy.

    Stage
    Not phased
    Ages
    65 to 82
    Site
    New York Harbor Health Care System - Dept of Veterans Affairs, New York, New York
    Locations
    24 in total
    Run by
    Dartmouth-Hitchcock Medical Center

    See if you can join NCT05612347 on ClinicalTrials.gov

  23. Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

    This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Columbia University, New York, New York
    Locations
    56 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT06128551 on ClinicalTrials.gov

  24. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Columbia University Medical Center, New York, New York
    Locations
    32 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT06445062 on ClinicalTrials.gov

  25. A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy

    The researchers are doing this study to find out whether the combination of botensilimab and balstilimab (BOT/BAL), followed by balstilimab alone, is an effective treatment for people with microsatellite stable (MSS) colorectal cancer or colorectal liver metastases (CRLM) who have measurable residu…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
    Locations
    7 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07227636 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.